JP2019535295A - がんの診断における後成的染色体相互作用の応用 - Google Patents

がんの診断における後成的染色体相互作用の応用 Download PDF

Info

Publication number
JP2019535295A
JP2019535295A JP2019528462A JP2019528462A JP2019535295A JP 2019535295 A JP2019535295 A JP 2019535295A JP 2019528462 A JP2019528462 A JP 2019528462A JP 2019528462 A JP2019528462 A JP 2019528462A JP 2019535295 A JP2019535295 A JP 2019535295A
Authority
JP
Japan
Prior art keywords
chromosomal
sequence
nucleic acids
cancer
ligated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019528462A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019535295A5 (enExample
Inventor
ヘクター グランド，フランシス
ヘクター グランド，フランシス
セルヴァム ラマダス，アラウル
セルヴァム ラマダス，アラウル
アコウリチェフ，アレクサンドル
ハンター，ユアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Biodynamics PLC
Original Assignee
Oxford Biodynamics PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Biodynamics PLC filed Critical Oxford Biodynamics PLC
Publication of JP2019535295A publication Critical patent/JP2019535295A/ja
Publication of JP2019535295A5 publication Critical patent/JP2019535295A5/ja
Priority to JP2022183117A priority Critical patent/JP7579003B2/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00—Reaction characterised by the enzymatic activity
    • C12Q2521/30—Phosphoric diester hydrolysing, i.e. nuclease
    • C12Q2521/301—Endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00—Reaction characterised by the enzymatic activity
    • C12Q2521/50—Other enzymatic activities
    • C12Q2521/501—Ligase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2523/00—Reactions characterised by treatment of reaction samples
    • C12Q2523/10—Characterised by chemical treatment
    • C12Q2523/101—Crosslinking agents, e.g. psoralen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
    • C12Q2565/50—Detection characterised by immobilisation to a surface
    • C12Q2565/501—Detection characterised by immobilisation to a surface being an array of oligonucleotides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019528462A 2016-12-01 2017-11-30 がんの診断における後成的染色体相互作用の応用 Pending JP2019535295A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022183117A JP7579003B2 (ja) 2016-12-01 2022-11-16 がんの診断における後成的染色体相互作用の応用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662428893P 2016-12-01 2016-12-01
US62/428,893 2016-12-01
PCT/GB2017/053615 WO2018100381A1 (en) 2016-12-01 2017-11-30 Application of epigenetic chromsomal interactions in cancer diagnostics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022183117A Division JP7579003B2 (ja) 2016-12-01 2022-11-16 がんの診断における後成的染色体相互作用の応用

Publications (2)

Publication Number Publication Date
JP2019535295A true JP2019535295A (ja) 2019-12-12
JP2019535295A5 JP2019535295A5 (enExample) 2021-01-14

Family

ID=60702831

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019528462A Pending JP2019535295A (ja) 2016-12-01 2017-11-30 がんの診断における後成的染色体相互作用の応用
JP2022183117A Active JP7579003B2 (ja) 2016-12-01 2022-11-16 がんの診断における後成的染色体相互作用の応用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022183117A Active JP7579003B2 (ja) 2016-12-01 2022-11-16 がんの診断における後成的染色体相互作用の応用

Country Status (12)

Country Link
US (2) US11560597B2 (enExample)
EP (2) EP4357463A3 (enExample)
JP (2) JP2019535295A (enExample)
KR (1) KR102481242B1 (enExample)
CN (1) CN110234769B (enExample)
AU (1) AU2017367245B2 (enExample)
CA (1) CA3045070A1 (enExample)
ES (1) ES2971286T3 (enExample)
MY (1) MY190153A (enExample)
PL (1) PL3548633T3 (enExample)
TW (1) TWI865427B (enExample)
WO (1) WO2018100381A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022532108A (ja) * 2019-05-08 2022-07-13 オックスフォード バイオダイナミックス ピーエルシー 前立腺がんおよびリンパ腫の染色体コンフォメーションマーカー

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118506860B (zh) * 2024-07-18 2024-10-08 广州女娲生命科技有限公司 药物表观遗传安全性评价的检测分析方法及系统

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009500031A (ja) * 2005-07-04 2009-01-08 エラスムス ユニバーシティ メディカル センター 染色体コンフォメーションキャプチャ−オン−チップ（４ｃ）アッセイ
JP2010515449A (ja) * 2007-01-11 2010-05-13 エラスムス ユニバーシティ メディカル センター 環状染色体コンホメーション捕捉（４ｃ）

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0603251D0 (en) * 2006-02-17 2006-03-29 Isis Innovation DNA conformation
CA2609172A1 (en) * 2007-10-31 2009-04-30 University Of Utah Research Foundation Immunotherapy compositions for use with targeted therapy in the treatment of cancer
GB0810051D0 (en) * 2008-06-02 2008-07-09 Oxford Biodynamics Ltd Method of diagnosis
WO2010036323A1 (en) 2008-09-25 2010-04-01 University Of Massachusetts Medical School Method of identifing interactions between genomic loci
EP2366162A1 (en) * 2008-11-18 2011-09-21 Collabrx, Inc. Individualized cancer treatment
CA2804450C (en) * 2010-07-09 2022-10-11 Max Jan van Min 3-d genomic region of interest sequencing strategies
US20140056898A1 (en) * 2011-02-24 2014-02-27 Bo Zhang Combination therapies comprising anti-erbb3 agents
EP2710146A2 (en) * 2011-05-18 2014-03-26 Life Technologies Corporation Chromosome conformation analysis
AU2013280644B2 (en) * 2012-06-26 2018-08-02 Jeffrey A. BACHA Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
CN102827935B (zh) * 2012-08-29 2013-12-18 北京大学人民医院 定量检测FIP1L1-PDGFRA融合基因mRNA水平的试剂盒
GB201320351D0 (en) * 2013-11-18 2014-01-01 Erasmus Universiteit Medisch Ct Method
JP2018518203A (ja) 2015-06-24 2018-07-12 オックスフォード バイオダイナミックス リミテッド エピジェネティックな染色体相互作用
EP3390656B1 (en) * 2015-12-14 2020-04-08 The General Hospital Corporation Methods of detecting insulator dysfunction and oncogene activation for screening, diagnosis and treatment of patients in need thereof
GB201608000D0 (en) 2016-05-06 2016-06-22 Oxford Biodynamics Ltd Chromosome detection

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009500031A (ja) * 2005-07-04 2009-01-08 エラスムス ユニバーシティ メディカル センター 染色体コンフォメーションキャプチャ−オン−チップ（４ｃ）アッセイ
JP2010515449A (ja) * 2007-01-11 2010-05-13 エラスムス ユニバーシティ メディカル センター 環状染色体コンホメーション捕捉（４ｃ）

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022532108A (ja) * 2019-05-08 2022-07-13 オックスフォード バイオダイナミックス ピーエルシー 前立腺がんおよびリンパ腫の染色体コンフォメーションマーカー
JP7617029B2 (ja) 2019-05-08 2025-01-17 オックスフォード バイオダイナミックス ピーエルシー 前立腺がんおよびリンパ腫の染色体コンフォメーションマーカー

Also Published As

Publication number Publication date
WO2018100381A1 (en) 2018-06-07
CA3045070A1 (en) 2018-06-07
TW201842190A (zh) 2018-12-01
ES2971286T3 (es) 2024-06-04
TWI865427B (zh) 2024-12-11
NZ753716A (en) 2024-05-31
MY190153A (en) 2022-03-31
KR20190086569A (ko) 2019-07-22
CN110234769B (zh) 2024-06-07
US11560597B2 (en) 2023-01-24
KR102481242B1 (ko) 2022-12-23
AU2017367245B2 (en) 2020-09-24
EP3548633B1 (en) 2024-01-24
PL3548633T3 (pl) 2024-04-02
JP2023027076A (ja) 2023-03-01
US20230082230A1 (en) 2023-03-16
EP4357463A3 (en) 2024-07-17
EP3548633A1 (en) 2019-10-09
EP3548633C0 (en) 2024-01-24
JP7579003B2 (ja) 2024-11-07
AU2017367245A1 (en) 2019-06-06
CN110234769A (zh) 2019-09-13
EP4357463A2 (en) 2024-04-24
US20190338367A1 (en) 2019-11-07

Similar Documents

Publication Publication Date Title
JP7297015B2 (ja) エピジェネティックな染色体相互作用
JP7631400B2 (ja) 遺伝子調節
JP7579003B2 (ja) がんの診断における後成的染色体相互作用の応用
AU2018344573A1 (en) Biomarker
JP2025108590A (ja) 診断用染色体マーカー
JP7617029B2 (ja) 前立腺がんおよびリンパ腫の染色体コンフォメーションマーカー
JP7045086B2 (ja) 分類法
HK40111334A (en) Application of epigenetic chromsomal interactions in cancer diagnostics
JP2023545364A (ja) 疾患マーカー
CN116507740A (zh) 检测作为用于纤维化例如硬皮病的标志物的染色体构象
HK40013967A (en) Application of epigenetic chromsomal interactions in cancer diagnostics
HK40013967B (en) Application of epigenetic chromsomal interactions in cancer diagnostics
TW202302862A (zh) 染色體交互作用標記物
CN117795098A (zh) 染色体相互作用标志物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201127

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220401

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220719